Section 13.1: Collaborative Practice Agreements & Drug Therapy Management

Collaborative Practice Agreements & Drug Therapy Management (DTM)

In Texas, the practice of pharmacy is legally defined to include "drug therapy management" (DTM) under the delegated authority of a physician. Unlike some states that grant pharmacists broad independent prescriptive authority, Texas operates strictly under a collaborative practice model. DTM is not an independent pharmacist function; it is a delegated medical act. The legal framework governing DTM is established jointly by the Texas Pharmacy Act (Texas Occupations Code Chapter 554) and the Medical Practice Act (Texas Occupations Code Chapter 157), and is codified under Texas State Board of Pharmacy (TSBP) Rule §295.13.

Definition and Scope of DTM

Drug Therapy Management is defined as the performance of specific acts delegated by a physician in a written protocol. A pharmacist acting under a collaborative practice agreement (CPA) is authorized to collect and review patient drug histories, order or perform routine patient assessment procedures (such as taking vital signs), order drug-therapy related laboratory tests, and implement or modify drug therapy according to the written protocol.

It is vital to understand that a pharmacist cannot diagnose patients. DTM activities may only begin after a physician has performed a diagnosis, conducted an initial patient assessment, and issued an initial drug therapy order. The pharmacist's role is to manage, optimize, and modify the drug therapy within the boundaries of the protocol established for that patient or disease state.

Setting Restrictions for Prescription-Signing Authority

A critical legal nuance under Texas law is the distinction between performing general DTM (such as modifying dosages or ordering labs) and the authority to sign prescription drug orders (prescribing). While a pharmacist can perform general DTM in any setting (including a Class A community pharmacy), the authority to sign prescription drug orders is highly restricted. Under TSBP Rule §295.13 and the Medical Practice Act, a pharmacist may only sign or issue a prescription drug order under a CPA in the following specific practice settings:

1. Hospitals (Class C permits)
2. Hospital-based clinics
3. Academic healthcare institutions
4. Federally Qualified Health Centers (FQHCs)

Furthermore, the facility where the pharmacist practices must have bylaws and medical staff policies that explicitly permit a physician to delegate the management of a patient's drug therapy, including the authority to sign prescription drug orders, to a pharmacist.

Dangerous Drugs vs. Controlled Substances

Even when practicing in an authorized institutional setting with supporting facility bylaws, a pharmacist's prescription-signing authority is strictly limited to dangerous drugs (non-controlled legend substances). Pharmacists in Texas have no authority to sign or issue prescription drug orders for Schedule II, III, IV, or V controlled substances. Any modification to a controlled substance regimen must be directly authorized and signed by the supervising physician.

Education, Training, and CE Requirements

To engage in DTM under a written protocol in Texas, a pharmacist must meet rigorous professional development standards. Before initiating DTM, the pharmacist must complete at least 6 hours of continuing education (CE) related to drug therapy offered by an ACPE-approved provider within the year preceding the initiation of DTM.

To maintain DTM eligibility, the pharmacist must annually complete 6 hours of CE related to the specific drug therapy they are managing under the protocol. These 6 hours are not additional hours beyond the 30 hours of total CE required for biennial pharmacist license renewal; they can be counted toward the 30-hour total, but they must be specifically focused on the therapeutic areas managed under the CPA.

Protocol Requirements and Documentation

The written protocol is the foundational legal document of any collaborative practice agreement. The protocol must contain specific, actionable parameters and cannot be vague. Under TSBP rules, a valid DTM protocol must contain:

• A statement identifying the individual physician and pharmacist(s) authorized to participate.
• A list of the specific disease states and drug categories covered under the agreement.
• The exact types of decisions and modifications the pharmacist is authorized to make.
• A list of routine assessments and laboratory tests the pharmacist may order.
• Explicit procedures the pharmacist must follow when modifying a drug therapy.
• A description of the mechanism for reporting and documenting the pharmacist's clinical activities to the delegating physician.
• Plan for the physician to review the pharmacist's actions on a regular basis.

Review and Retention Timelines

Protocols must be reviewed, signed, and dated annually by both the supervising physician and the pharmacist. If any changes are made to the protocol during the year, an updated protocol must be signed.

The pharmacist is required to maintain a copy of the written protocol for inspection by the TSBP. Under Texas law, DTM protocols and any associated amendments must be retained for at least 7 years after the date of expiration or the last amendment. This is a significant extension compared to the standard 2-year retention period for general pharmacy records in Texas.

Notification and Physician Supervision

Pharmacists must submit a notification of physician delegation to the TSBP using the prescribed board forms prior to starting DTM. Additionally, if there are any changes to the delegation agreement or protocol, the pharmacist must notify the TSBP within 10 days of the change.

Physician supervision must be active and continuous. The delegating physician must remain available for daily consultation with the pharmacist, must periodically review the pharmacist's DTM records and patient outcomes, and must maintain corresponding liability for the delegated medical acts. The physician-pharmacist relationship is structured to ensure that the physician remains the head of the healthcare team, providing oversight and maintaining ultimate responsibility for patient care.

Exam Traps and Legal Nuances

[!WARNING] Prescribing in Community Pharmacies: A common MPJE exam trap involves a community (Class A) pharmacist signing a prescription for a dangerous drug under a physician protocol. On the exam, remember: No pharmacist in a Class A pharmacy may sign a prescription. They may only implement or modify therapy by modifying an existing order, or the physician must sign the new prescription order.

[!CAUTION] Controlled Substances: A pharmacist can never sign a prescription for a controlled substance under DTM, even in a hospital or clinic setting. If a question suggests a pharmacist is signing a refill for a Schedule IV drug under a protocol, it is illegal.